C4U Corporation (“C4U”) is pleased to announce that a patent for the invention titled “Method for Producing Cas3 Protein” was issued on January 9, 2026, as Patent No. 7802303.
As previously announced, the patent for this invention was issued in Europe on December 24, 2025.
This patented technology relates to a method for producing Cas3 protein, one of the key protein components of the CRISPR-Cas3 genome editing system. This method enables the high-purity and high-yield production of recombinant proteins while maintaining their biological activity. As Cas3 protein is a vital component of the CRISPR-Cas3 system, this technology will be applied to both diagnostic and genome editing applications.
C4U will continue to strengthen its intellectual property portfolio for CRISPR-Cas3 technology worldwide and accelerate its application across a wide range of sectors, including the pharmaceutical field.
About C4U Corporation
C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by the University of Osaka for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape. https://www.crispr4u.jp/en/
Contact
C4U Corporation
Address：Yamadaoka 2-8, Suita, Osaka 565-0871, Japan
E-mail：info@crispr4u.com
